NEW YORK (GenomeWeb News) – Gentronix and Apredica said today that they will collaborate on providing drug-discovery support services with a focus on predictive toxicology.

Watertown, Mass.-based Apredica is an ADME-Tox contract research laboratory and has been working with Gentronix on developing "a joint predictive toxicology offering based on a set of assays that accurately predict many known mechanisms of human toxicities," the firm's president, Katya Tsaioun, said in a statement.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Genome Research this week: mitochondrial and nuclear gene fusions in cancer, role of genomic imprinting in tissue-specific gene expression, and more.

Maria Freire from the Foundation for the NIH calls for "politically popular pledges of support" for the NIH to turn into support for increased funding for the agency.

A Thomson Reuters analysis indicates that the life sciences, rather than the tech sector, are increasingly driving global innovation.

The White House says ethical discussions about genome editing of the human germline are needed.